Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B And Hepatitis Delta Data Accepted For Presentation At AASLD's The Liver Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology, Inc. (NASDAQ:VIR) has announced that eight abstracts from its chronic hepatitis B and chronic hepatitis delta clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting in November 2023. The presentations include seven poster presentations and one late-breaking oral presentation.
October 11, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vir Biotechnology's research on chronic hepatitis B and delta has been recognized by the AASLD, which could potentially boost the company's reputation in the biotech industry.
The acceptance of Vir Biotechnology's abstracts for presentation at a prestigious event like the AASLD's The Liver Meeting indicates recognition of the company's work in the field of liver diseases. This could potentially enhance the company's reputation, attract more investors, and positively impact its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100